Imipenem/Cilastatin Sodium in the Treatment of Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis
- 1 January 1994
- journal article
- clinical trial
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 14 (3) , 182-186
- https://doi.org/10.1159/000168711
Abstract
Imipenem/cilastatin sodium is a new thienamycin class of antibiotic with a broad spectrum of bactericidal activities. It may be a suitable single first-line therapy for the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients. Fifty episodes of CAPD peritonitis were treated with imipenem/cilastatin sodium. On presentation, all patients were given an intravenous loading dose of 1 g of imipenem/cilastatin sodium followed by intraperitoneal imipenem/cilastatin sodium for 10 days. During 1989 (30 episodes), 20 mg imipenem/cilastatin sodium was added to each 2-liter bag of peritoneal dialysis (PD) fluid for 10 days. The primary response rate as defined by polymorphonuclear neutrophilsKeywords
This publication has 0 references indexed in Scilit: